Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France.
Saved in:
| Title: | Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France. |
|---|---|
| Authors: | Pérol M; Department of Medical Oncology, Centre Léon Bérard, Lyon, France. Electronic address: maurice.perol@lyon.unicancer.fr., Audigier-Valette C; Department of Thoracic Oncology, Hôpital Sainte Musse, Toulon, France., Léna H; Centre hospitalier universitaire Pontchaillou, Rennes, France., Massiani MA; Department of Medical Oncology, Institut Curie, Saint-Cloud, France., Quantin X; Institut du Cancer de Montpellier, Montpellier, France., Santorelli M; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA., Apert M; Outcomes Research, MSD France, Puteaux, France., Spampinato A; Medical Affairs, MSD France, Puteaux, France., Burke T; Outcomes Research, MRL, Merck & Co. Inc., Rahway, NJ, USA., Chouaid C; Pneumonology Unit, Centre Hospitalier Intercommunal, Créteil, France. |
| Source: | Respiratory medicine and research [Respir Med Res] 2026 May; Vol. 89, pp. 101238. Date of Electronic Publication: 2025 Dec 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Masson SAS Country of Publication: France NLM ID: 101746324 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2590-0412 (Electronic) Linking ISSN: 25900412 NLM ISO Abbreviation: Respir Med Res Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 2590-0412 |
|---|---|
| DOI: | 10.1016/j.resmer.2025.101238 |
